# Relay Therapeutics

Source: https://onco.cc/companies/relay-therapeutics/  
OnCo record `relay-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Relay Therapeutics uses computer simulations of how proteins move to design precise cancer pills. Its lead drug, zovegalisib, targets a mutated growth protein called PI3K-alpha in breast cancer while sparing the normal version.

## Summary

Relay Therapeutics is a Cambridge, Massachusetts precision medicine company that combines computational modelling of protein motion with experimental chemistry. Its lead programme, zovegalisib (RLY-2608), is a mutant-selective, allosteric PI3K-alpha inhibitor that the company lists in phase 3 for PIK3CA-mutant breast cancer and in a phase 1/2 trial for vascular anomalies. RLY-8161, an NRAS inhibitor, is in a phase 1/2 trial in NRAS-mutant melanoma and other NRAS-mutant solid tumours. Lirafugratinib (RLY-4008), an FGFR2-selective inhibitor developed in FGFR2-fusion cholangiocarcinoma, was out-licensed to Elevar Therapeutics in December 2024. A non-oncology alpha-galactosidase A programme for Fabry disease is also listed. Relay completed its Nasdaq IPO in July 2020, selling 20 million shares at 20 US dollars per share according to its final prospectus.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Cambridge, MA
- Type: biotech
- Website: https://relaytx.com/
- Ticker: RLAY

## Notes

- IPO gross proceeds computed from the prospectus (20 million shares at 20 US dollars); final amount including the option was not confirmed. Founding year not sourced. The ai-drug-design tag reflects the company's computational platform as described on its site.

## Sources

- Official website: https://relaytx.com/
- Pipeline: https://relaytx.com/pipeline/
- IPO prospectus (SEC 424B4): https://www.sec.gov/Archives/edgar/data/1812364/000119312520194016/d904779d424b4.htm

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Melanoma](https://onco.cc/cancers/melanoma/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [AI-driven drug & target discovery](https://onco.cc/technologies/ai-drug-design/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [FGFR2](https://onco.cc/targets/fgfr2/), [PIK3CA / PI3K-alpha](https://onco.cc/targets/pik3ca/)
- drugs: [Zovegalisib](https://onco.cc/drugs/zovegalisib/)
- companies: [Boxer Capital](https://onco.cc/companies/boxer-capital/)
- trials: [Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer](https://onco.cc/trials/nct06982521/)

---
JSON: https://onco.cc/api/v1/entities/relay-therapeutics.json